Eli Lilly's Vision for 'Beyond Obesity Drugs'—The $2.4 Billion Acquisition and the Future of the 'In Vivo' Revolution

In February 2026, Eli Lilly and Company is pursuing multiple initiatives, including M&A and partnerships, to utilize its cash reserves against the backdrop of the growth of its GLP-1 receptor agonists, 'Mounjaro' and 'Zepbound.' In particular, the acquisition agreement with Orna Therapeutics (valued at up to $2.4 billion) is positioned as an example of its efforts toward a next-generation drug discovery platform.